Contact Us
菜单

You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.

Cancel  Continue
About Us

Overview

Evive Biotech, a subsidiary of Yifan Pharmaceutical, is a global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for patients worldwide. We leverage our proprietary technology platforms to advance a series of innovative drug candidates for oncology, inflammatory and metabolic diseases. Founded in 2004, we currently have operations in the US, EU, Singapore, and China. As one of the top biopharmaceutical companies to develop innovative therapies from China for the world, Evive adopts a holistic approach for drug development, combining exceptional preclinical and clinical research capabilities with our world-class in-house manufacture and regulatory expertise as well as extensive global drug development experience. Through partnerships with industry, physicians, and regulatory authorities, we strive to bring revolutionary remedies to the global markets quickly and efficiently to address unmet medical needs, making a real and lasting difference for patients and their families worldwide.

  • 2004
    • Evive Biotech founded
  • 2005
    • Filed the first patent for rhIL-22
  • 2007
    •  Early development of therapeutic rhIL-22
  • 2009

    • Established DikineTM platform and initiated F-652 (rhIL-22 dimer) project

    • Completed F-627 preclinical studies
  • 2010
    • Initiated and completed Ph I study for F-627
  • 2011
    • F-627 CMO manufacturing in US
  • 2012
    • Received F-627 China IND approval
    • Initiated F-627 Ph II study in US and Europe
    • Launched cGMP manufacturing plant project
  • 2014
    • Completed F-627 Ph II study in US and Europe
    • Initiated F-627 China Ph II study
  • 2015
    • Initiated two Ph II studies in US for F-652 to treat patients with GvHD (acute graft versus host disease) and AH (acute alcoholic hepatitis)
    • Completed F-627 China Phase II study
    • Received F-652 China IND approval
    • Completed F-627 first GMP run
  • 2016
    • F-627 US Ph III IND approval
    • Initiated F-627 Ph III study (04) in US and Europe
  • 2017
    • F-627 SPA agreement with U.S. FDA
    • F-627 China Ph III IND approval
    • Completed F-652 China Ph I study
  • 2018
    • F-627 Ph III study (04) met primary and secondary end points
    • Initiated F-627 second global Ph III study (05)
    • Completed F-652 Ph IIa study to treat AH
  • 2019
    • Received Orphan-Drug Designation from U.S. FDA for F-652 for the treatment of Acute Graft vs Host Disease
  • 2020
    • F-627 China Ph III study met primary endpoints
    • Completed F-652 Ph IIa study to treat GvHD
    • F-627 second global Ph III study (05) met primary endpoints
    • Rebranded Generon to Evive Biotech
  • 2021
    • Formed joint venture with Dr. Xiao Qiang Yan to further develop bi-specific antibody platform ITab™

    • F-627 BLA/MAA Accepted by US FDA, EMA

    • Partnered with Chia Tai Tianqing for F-627’s Commercialization in Mainland China
  • 2022

    • F-627 NDA Accepted by China NMPA

    • Partnered with APOGEPHA for F-627’s Commercialization in Germany and Switzerland

    • Partnered with Acrotech Biopharma for F-627 Commercialization in the US

  • 2023

    • Ryzneuta® NDA Approved by China's NMPA

    • Ryzneuta® Approved by FDA

  • 2024

    • Ryzneuta® Approved by European Commission (EC)

Our Mission

Become a global commercial-stage biopharmaceutical company dedicated to the development of innovative medicines for patients with unmet medical needs in the areas of oncology, inflammatory or metabolic diseases.

Key Goals

  • Build strong global drug development and commercialization capabilities, including cutting-edge innovative R&D centers, strong clinical development teams, well-recognized regulatory affairs experts, large-molecule manufacturing facilities meeting international GMP standards, and specialized commercial teams.

  • Generate a broad product pipeline with worldwide commercialization of F-627 as a novel treatment for chemotherapy-induced neutropenia, one indication of F-652 submitted for market approval in China, two indications in late-stage clinical development, and multiple product candidates in early clinical or pre-clinical development stages that have been developed with first-in-class or best-in-class potential by in-house R&D teams.

  • Establish a global drug development infrastructure with efficient organization and management systems for compliance, sustainable company culture for long-term development, and access to Chinese and global financial markets.

Our Locations
China

Beijing

Shanghai

Hong Kong

US

San Francisco, CA

Princeton, NJ

Ireland

Singapore

  • China
    Beijing
    Clinical Development
Manufacturing
Regulatory Affairs
    Shanghai

    Preclinical
    CMC

  • US
    San Francisco, CA
    Preclinical
  • US
    Princeton, NJ
    Clinical Development
Regulatory Affairs
  • Ireland
  • Singapore
  • China
    Hong Kong

You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.

Cancel  Continue

You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.

Cancel  Continue